(secondQuint)Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors.

 Part one is a single-dose study on tolerance and pharmacokinetics, in which 21-42 patients with advanced solid tumors would be enrolled.

 Patients will receive escalating dose groups of HWH340 tablet.

 Part two is a multiple-dose study on tolerance and pharmacokinetics.

 Based on the safety assessment, three or four groups would be chosen to conduct the study.

 9-24 patients with advanced solid tumors will be enrolled.

.

 Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors@highlight

This is an open-label, dose-escalation, phase I clinical trial study to investigate the safety and tolerability of HWH340.

 In addition, the pharmacokinetic characteristics will also be investigated.

 Two parts are included in this study.

